Oculis Phase 3 Trials for Diabetic Macular Edema Fail Primary Endpoint
Event summary
- Oculis' Phase 3 DIAMOND trials for OCS-01 eye drops in diabetic macular edema (DME) failed to meet the primary endpoint of mean change in best corrected visual acuity (BCVA) at week 52.
- Secondary endpoint of retinal thickness showed substantial and persistent reduction with OCS-01 vs vehicle in both trials.
- Oculis will not pursue FDA regulatory filing for OCS-01 in DME and will focus resources on Privosegtor and Licaminlimab programs.
- Company has $278 million in cash as of March 31, 2026, providing runway into 2H 2029.
The big picture
Oculis' failure to meet the primary endpoint in its Phase 3 DME trials marks a significant setback in its ophthalmology portfolio. The company's strategic pivot to neuro-ophthalmology and dry eye disease programs reflects broader industry trends toward precision medicine and targeted therapies. With a strong cash position, Oculis has the financial flexibility to pursue these new avenues, but success will depend on execution and regulatory approvals.
What we're watching
- Pipeline Focus
- Whether Oculis can successfully advance its Privosegtor and Licaminlimab programs to offset the DME setback.
- Financial Discipline
- The pace at which Oculis burns through its $278 million cash reserve as it shifts focus to other programs.
- Regulatory Strategy
- How Oculis will position its other candidates for regulatory approval given the DME trial outcome.